Dr.Reddy's launches anti-cancer injection in US market
The drug, which is used to treat certain types of cancer, was earlier approved by the US Food and Drug Administration (USFDA), DRL said in a statement.
DR. REDDY'S
-
Nestlé India, Dr Reddy’s form JV to bring innovative nutraceutical brands to India
The JV Company will be headquartered in Hyderabad, it will leverage the capabilities as well as services of the Nestlé Group and Dr Reddy’s. The Nestlé Group will licence brands such as Nature's Bounty, Osteo Bi-Flex, Ester-C, Resource High Protein, Optifast, Resource Diabetic, Peptamen, Resource Renal and Resource Dialysis. Dr Reddy’s will license brands such as Rebalanz, Celevida, Antoxid, Kidrich-D3, Becozinc in the nutrition, and OTC segments.
-
Dr. Reddy's Laboratories launches Regadenoson Injection 0.4mg/5mL in US market
-
Dr. Reddy's inks deal with DNDi to develop drugs for 'neglected tropical diseases'
-
Dr. Reddy's inks pact with Singapore firm Prestige BioPharma to commercialise Trastuzumab biosimilar in select countries
-
Dr. Reddy's eyes Sputnik vaccine exports after domestic struggle
-
Russia's single-dose Sputnik Light can be new hope to fasten Covid vaccination drive in India
-
Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex in US
-
New psoriasis drug study yields positive results: Dr Reddy's
-
At the helm at Dr. Reddy's, Erez Israeli will have his task cut out
Join the community of 2M+ industry professionals
Subscribe to our Daily Newsletter
Advertisement
More in DR. REDDY'S
-
-
Indian pharma takes M&A route to build a global footprint
Last week Dr. Reddy's acquired a portfolio of eight complex generics in the US from Teva in a deal worth $350 million.
-
Health ministry plans to revamp regulatory rules for biosimilar drugs
Officials say the new norms will be finalised after consultations with the industry, academic institutions and stakeholders like the civil society.
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
